Skip to main
NUVB
NUVB logo

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio Inc. demonstrates a strong positive outlook due to the robust efficacy profile of its lead product candidate, taletrectinib, which achieved an 88.8% confirmed overall response rate and extends median duration of response and progression-free survival significantly in TKI-naive ROS1+ non-small cell lung cancer (NSCLC) patients. The company's financial position is solidified by ending 2024 with $502.7 million in cash, cash equivalents, and marketable securities, which is expected to support operations until reaching profitability. Furthermore, the anticipated market penetration of 35% in the first-line setting aligns with revised NCCN guidelines, positioning Nuvation Bio favorably in the competitive oncology landscape.

Bears say

Nuvation Bio faces significant risks that could adversely impact its financial performance, including the potential for negative clinical proof-of-concept data for its therapeutic candidates, which could hinder progress in obtaining necessary approvals. Additionally, there is concern regarding the commercial uptake of its lead product, taletrectinib, which may be adversely affected by intense competition and other market dynamics, leading to projected financial losses. The company's recent financial results show a net loss of $0.15 per share for Q4 2024, with forecasts for 2025 indicating a further increased loss, suggesting a deteriorating financial outlook.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.